睾酮替代治疗对性腺功能减退男性的获益
该回顾性倾向匹配队列研究利用TriNetX数据库2005至2020年57家医疗机构的电子病历数据,比较40至80岁性腺功能减退男性接受与未接受睾酮替代治疗(TRT)的3年结局。结果显示TRT组死亡率、房颤、卒中和前列腺癌发生率均较低,但数据库可能遗漏部分病例。
要点
- TRT与性腺功能减退男性3年死亡率、房颤、卒中和前列腺癌风险降低相关。
- 研究为回顾性倾向匹配设计,结果需前瞻性研究验证。
- 数据库可能遗漏卒中、前列腺癌和心血管疾病病例,解读需谨慎。
核心结论
- 在性腺功能减退男性中,使用TRT与较低的死亡率、房颤、卒中和前列腺癌发生率相关。
研究设计与样本
- 回顾性倾向匹配队列研究,利用TriNetX数据库2005至2020年57家医疗机构的去标识电子病历数据。
- 纳入40至80岁诊断为性腺功能减退的男性,比较处方TRT与未处方TRT两组,经倾向匹配后分析3年结局。
主要发现
- 共识别163,456例性腺功能减退男性,倾向匹配后纳入133,584例。
- TRT组死亡率3.1% vs 3.6%(RR 0.886,P < .001)。
- TRT组房颤发生率3.6% vs 4.0%(RR 0.900,P < .001)。
- TRT组卒中发生率1.6% vs 1.8%(RR 0.898,P < .011)。
- TRT组前列腺癌发生率1.9% vs 2.9%(RR 0.648,P < .001)。
临床怎么用
- 对于确诊性腺功能减退的40至80岁男性,处方TRT时可将死亡率、房颤、卒中和前列腺癌风险降低作为潜在获益与患者讨论。
- 需结合个体情况评估TRT的风险与获益,并注意数据库可能遗漏部分事件。
局限性
- 回顾性研究设计,可能存在残余混杂。
- 数据库可能遗漏卒中、前列腺癌和心血管疾病发病病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hypogonadism is defined by consistently low serum testosterone levels in conjunction with clinical symptoms. Testosterone replacement therapy (TRT) can be used to achieve physiologic levels of testosterone. Testosterone deficiency is associated with increased mortality and poorer health outcomes. PURPOSE: To compare rates of mortality, atrial fibrillation (AF), stroke, myocardial infarction (MI), and prostate cancer in hypogonadal men who received TRT versus those who did not. METHODS: The TriNetX database was utilized to access deidentified, retrospective propensity matched EMR data from 57 participating health care organizations between 2005 to 2020. Cohorts included males 40 to 80 years old diagnosed with hypogonadism who were prescribed TRT versus no TRT. Propensity matching was performed to reduce bias and balance confounding factors between the 2 groups. The following 3-year outcomes were analyzed: mortality, AF, stroke, MI, and prostate cancer. RESULTS: There were 163,456 male patients identified with hypogonadism, and 133,584 were included after propensity matching. There was a lower mortality rate, (3.1% vs 3.6%; RR, 0.886; P < .001), decreased risk of AF (3.6% vs 4.0%; RR 0.900; P < .001), less stroke (1.6% vs 1.8%; RR, 0.898; P < .011), and fewer cases of prostate cancer (1.9% vs 2.9%; RR 0.648; P < .001) for patients on TRT. CONCLUSIONS: Using TRT is associated with moderately lower rates of mortality, atrial fibrillation, stroke, and prostate cancer in hypogonadal men versus no TRT. There is potential for missed cases of stroke, prostate cancer, and cardiovascular disease incidence not captured by the database. As prescriptions of TRT increase, understanding risks and benefits will help guide future practice.
引用
- Blackwell KM, Buckingham H, Paul KK, et al. Benefits of Testosterone Replacement Therapy in Hypogonadal Males. J Am Board Fam Med. 2024. PMID: 39978846. doi:10.3122/jabfm.2024.240025R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。